Source:http://linkedlifedata.com/resource/pubmed/id/21190996
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2011-2-25
|
| pubmed:abstractText |
We conducted a prospective randomized study to assess the optimal postremission therapy for adult acute myeloid leukemia in patients younger than 65 years in the first complete remission. A total of 781 patients in complete remission were randomly assigned to receive consolidation chemotherapy of either 3 courses of high-dose cytarabine (HiDAC, 2 g/m(2) twice daily for 5 days) alone or 4 courses of conventional standard-dose multiagent chemotherapy (CT) established in the previous JALSG AML97 study. Five-year disease-free survival was 43% for the HiDAC group and 39% for the multiagent CT group (P = .724), and 5-year overall survival was 58% and 56%, respectively (P = .954). Among the favorable cytogenetic risk group (n = 218), 5-year disease-free survival was 57% for HiDAC and 39% for multiagent CT (P = .050), and 5-year overall survival was 75% and 66%, respectively (P = .174). In the HiDAC group, the nadir of leukocyte counts was lower, and the duration of leukocyte less than 1.0 × 10(9)/L longer, and the frequency of documented infections higher. The present study demonstrated that the multiagent CT regimen is as effective as our HiDAC regimen for consolidation. Our HiDAC regimen resulted in a beneficial effect on disease-free survival only in the favorable cytogenetic leukemia group. This trial was registered at www.umin.ac.jp/ctr/ as #C000000157.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:AsouNorioN,
pubmed-author:FujiedaAtsushiA,
pubmed-author:FujisawaShinS,
pubmed-author:HandaHiroshiH,
pubmed-author:HondaSumihisaS,
pubmed-author:KimuraYukihikoY,
pubmed-author:KiyoiHitoshiH,
pubmed-author:MiyamuraKoichiK,
pubmed-author:MiyawakiShuichiS,
pubmed-author:MiyazakiYasushiY,
pubmed-author:NagaiTadashiT,
pubmed-author:NakasekoChiakiC,
pubmed-author:NaoeTomokiT,
pubmed-author:OhnishiKazunoriK,
pubmed-author:OhnoRyuzoR,
pubmed-author:OhtakeShigekiS,
pubmed-author:SakamakiHisashiH,
pubmed-author:SakuraToruT,
pubmed-author:ShinagawaKatsujiK,
pubmed-author:TakahashiMasatomoM,
pubmed-author:TaniwakiMasafumiM,
pubmed-author:UsuiNorikoN,
pubmed-author:YagasakiFumiharuF,
pubmed-author:YamaneTakahisaT
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
24
|
| pubmed:volume |
117
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2366-72
|
| pubmed:meshHeading |
pubmed-meshheading:21190996-Adolescent,
pubmed-meshheading:21190996-Adult,
pubmed-meshheading:21190996-Antimetabolites, Antineoplastic,
pubmed-meshheading:21190996-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21190996-Cytarabine,
pubmed-meshheading:21190996-Dose-Response Relationship, Drug,
pubmed-meshheading:21190996-Humans,
pubmed-meshheading:21190996-Leukemia, Myeloid, Acute,
pubmed-meshheading:21190996-Leukocyte Count,
pubmed-meshheading:21190996-Middle Aged,
pubmed-meshheading:21190996-Remission Induction,
pubmed-meshheading:21190996-Survival Analysis,
pubmed-meshheading:21190996-Treatment Outcome,
pubmed-meshheading:21190996-Young Adult
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.
|
| pubmed:affiliation |
Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan. miyawaki@mail.wind.ne.jp
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|